Revenue
No reported data
Cabaletta Bio, Inc. (CABA)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Research & development | $142.7M | $97.2M | $55.4M | $39.3M | $32.5M | $21.4M | $11.7M | $4.5M |
| Operating expenses | $172.2M | $125.1M | $74.7M | $54.1M | $46.3M | $33.8M | $18.7M | $6.2M |
| Operating income | −$172.2M | −$125.1M | −$74.7M | −$54.1M | −$46.3M | −$33.8M | −$18.7M | −$6.2M |
| Net income | −$167.9M | −$115.9M | −$67.7M | −$53.0M | −$46.3M | −$33.3M | −$16.9M | −$12.2M |
| Basic EPSper diluted share | -$2.10 | -$2.34 | -$1.65 | -$1.81 | -$1.80 | -$1.44 | -$4.07 | -$6.87 |
| Diluted EPSper diluted share | -$2.10 | -$2.34 | -$1.65 | -$1.81 | -$1.80 | -$1.44 | -$4.07 | -$6.87 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jan 21, 2026Form 4 | Chang David J.Chief Medical Officer | BuyCommon Stock | 8.8K | $2.26 | $19.9K | 8.8K |
| Jan 21, 2026Form 4 | Binder GwendolynPresident, Science & Tech. | BuyCommon Stock | 11.3K | $2.19 | $24.8K | 31.3K |
| Jan 21, 2026Form 4 | Tomasello ShawnDirector | BuyCommon Stock · indirect | 22.7K | $2.21 | $50.2K | 22.7K |
| Jan 21, 2026Form 4 | Gavel SteveChief Commercial Officer | BuyCommon Stock | 22.2K | $2.27 | $50.3K | 22.2K |
| Jan 21, 2026Form 4 | Bollard CatherineDirector | BuyCommon Stock | 4.4K | $2.27 | $10.0K | 5.4K |